CYP4F2 genetic polymorphisms are associated with coronary heart disease in a Chinese population
- Changqing Yu†1, 2,
- Qingkai Yan†1, 2,
- Chunjiang Fu1, 2,
- Weibin Shi1, 2,
- Hongyong Wang1, 2,
- Chunyu Zeng1, 2 and
- Xukai Wang1, 2Email author
© Yu et al.; licensee BioMed Central Ltd. 2014
Received: 15 February 2014
Accepted: 14 April 2014
Published: 20 May 2014
To explore the relationship between CYP4F2 gene polymorphism and coronary heart disease (CHD) in a Chinese Han population.
We selected 440 CHD patients and 440 control subjects to perform a case - control study. Four SNPs (rs2108622, rs3093100, rs3093105 and rs3093135) in CYP4F2 gene were genotyped using polymerase chain reaction - restriction fragment length polymorphism (PCR - RFLP) methods. The genotype and haplotype distributions were compared between the case and the control group.
We found both rs2108622 and rs3093105 in CYP4F2 gene were associated with the risk for CHD (P <0.01). Haplotype analysis indicated that GGGT haplotype consisted by rs2108622-rs3093100-rs3093105-rs3093135 was associated with CHD risk (OR = 4.367, 95% CI: 2.241 ~ 8.510; P < 0.001), but GGTA haplotype was associated with decreased risk for CHD (OR = 0.450, 95% CI: 0.111 ~ 0.777; P <0.001).
CYP4F2 gene polymorphisms were associated with the risk of CHD in Chinese population.
KeywordsCoronary heart disease CYP4F2 gene Single nucleotide polymorphism
Coronary heart disease (CHD) is one of the most common diseases to influence the human health. Previous study indicated that the morbidity and mortality of CHD are very high . CHD was a complex polygenic disease resulting from the interaction between genetic variations and environmental factors . Although the exact genetic mechanism is unclear, some new susceptibility gene of the CHD have been reported recently, such as apolipoprotein (Apo) E , CYP8A1 , C5L2 , and interleukin (IL)-1 . Grammer et al.  analyzed the association between the apo E genotype, CRP and angiographic coronary artery disease (CAD). The concentration of CRP was similar in patients with stable CAD and in controls, but increased in patients presenting with acute coronary syndromes. In models adjusting for the main confounding variables, the ε2 allele was associated with a lower prevalence of angiographic CAD. Therefore, the authors concluded that the apo E genotype is associated with circulating CRP and risk for CAD. Xie et al.  performed a case–control study in a Chinese population and investigated the roles of polymorphisms in the CYP8A1 gene in CHD susceptibility. The authors found that CYP8A1 genetic polymorphisms are associated with CHD in Chinese population. Zheng et al.  identified a novel SNP-901G > A in C5L2 gene and found this SNP may be a genetic maker of CHD in the Han and Uygur population. Zhou et al. performed a meta-analysis of 13 independent case–control studies and suggested that there were no associations between IL-1 gene cluster polymorphisms and CHD. However, these genes have not been verified in different ethnicities.
20 - hydroxy eicosane arachidonic acid (20-HETE) is a metabolite of arachidonic acid (AA) produced in the kidney by cytochrome P450 enzymes. 20-HETE has potent actions on renal tubular and vascular function including: vasoconstriction secondary to inhibition of large conductance Ca2+-activated K+ channels in vascular smooth muscle cells and inhibition of Cl− transport in the thick ascending loop of Henle [7, 8]. 20-HETE has also been implicated as a second messenger mediating the inhibitory effects of dopamine, PTH, and angiotensin II on Na+-K+-ATPase activity and sodium transport in the proximal tubule [9, 10]. Some studies have suggested that increased levels of 20-HETE in the renal vasculature may underlie the development of hypertension , and, animal experiments showed that 20-HETE can cause vasospasm after hemorrhagic stroke, and it participates in the incidence and the development process of CHD and cerebral infarction . In the rat models with myocardial infarction, when the 20-HETE synthesis was suppressed, infarct size can be reduced . In hypertensive mice models, the increased 20-HETE production can lead to oxidative stress and endothelial cell damage, which results in the increased incidence of CHD .
CYP4F2 is the major synthase which can catalyze the arachidonic acid to generate 20-HETE. Recently, Stec et al. demonstrated that a SNP (rs2108622, V433M) in CYP4F2 gene may cause 20-HETE reduction from arachidonic acid . Fava et al.  studied the elderly patients with cerebral infarction in Sweden, and they found that V433M mutation in CYP4F2 gene was associated with cerebral infarction in male patients. A study  based on Japanese population found that G allele frequency of rs2108622 in male patients was higher than that in the controls. TCG haplotypes composed by rs3093135-rs1558139-rs2108622 is a risk factor for cerebral infarction in men . In addition, Fava et al.  also found CYP4F2 M433 carriers had significantly higher levels of waist, triglycerides, BP and a composite sum of MetS phenotypes (MetS score) beside lower HDL-cholesterol respect to V-homozygotes. However, the relation between CYP4F2 genetic polymorphisms with CHD in Chinese population remains unclear. In the present study, we utilized a case–control study to reveal the relationship between CYP4F2 gene polymorphism and CHD.
Materials and methods
The present study has been performed with the approval of the ethics committee of The Third Military Medical University and is in compliance with the Helsinki Declaration. The informed consents of the study were collected from all the candidate subjects.
A total of 440 hospitalized CHD patients in the Department of Cardiology, Daping Hospital, The Third Military Medical University were enrolled from September 2011 to April 2013. All these CHD patients were unrelated Han Chinese people. The patients were diagnosed CHD according to the criteria which was described previously . Briefly, CHD was defined as the presence of stenosis of more than 50% luminal diameter in at least one significant coronary artery on coronary angiography. Patients with ascertained congenital hypercoagulation, with proven disease limiting life expectance or with cocaine abuse were excluded.
During the same period, 440 persons in medical center of the same hospital were selected as the control group. All these control subjects were Han people whose age and sex were matched with the patient group. The subjects with cerebrovascular disease, neurological diseases, kidney disease, blood disorders, cancer, peripheral vascular disease, and autoimmune diseases were excluded from the control group. These control subjects have no the history of CHD and any symptom of CHD. The clinical characteristics including age, gender, height, weight, blood pressure, lipids profiles, fasting glucose, past medical history, drug history, smoking history, and alcohol history were collected.
2 mL of fasting venous blood was taken from antecubital vein and placed in EDTA-containing tubes. The genomic DNA extraction kit (Promega Corporation, United States) was used for DNA extraction from blood samples of the subjects according to the kit’s protocol.
There are 740 SNPs for the human CYP4F2 gene listed in the National Center for Biotechnology Information SNP database (http://www.ncbi.nlm.nih.gov/SNP). We also screened the data for the Tag SNPs on the International HapMap Project website (http://www.hapmap.org/). We searched tag SNP using Haploview 4.2 software in human HapMap Project database with the following criteria: r2 ≥ 0.8 and minimum gene frequency (MAF) ≥ 0.1. We found four tag SNPs (rs3093135, rs2108622, rs3093100, and rs1558139) in CYP4F2 gene.
Primers and PCR conditions of four SNPs
F : 5’-GGCAGGCAGTCATCCACA-3’
For each polymorphism, departure of the genotype distribution from that expected from Hardy-Weinberg equilibrium was assessed using the standard χ2 test or Fisher’s exact test. Genotype frequencies in cases and controls were compared by χ 2 tests. The genotype-specific risks were estimated as odds ratios (ORs). In all cases wild type genotype served as a reference group. Based on the genotype data of the genetic variations, we performed linkage disequilibrium (LD) analysis and haplotype-based case–control analysis, using the SHEsis software (http://analysis2.bio-x.cn/myAnalysis.php). In the haplotype-based case–control analysis, haplotypes with a frequency of <0.03 were excluded. Statistical significance was established at P <0.05. In the present study, we performed the case–control study included 440 CHD patients and 440 control subjects. The estimated power is 83.3%.
The characteristics of participants
Characteristics of the participants population
Hypertension (n, %)
Diabetes (n, %)
Smoking (n, %)
58.6 ± 13.5
25.2 ± 3.4
143.6 ± 21.1
88.1 ± 16.4
7.4 ± 3.6
3.1 ± 1.8
5.5 ± 2.2
1.3 ± 0.9
2.6 ± 1.4
58.5 ± 13.2
24.9 ± 3.5
124.2 ± 13.5
78.2 ± 13.2
4.6 ± 1.5
1.5 ± 1.0
4.0 ± 0.9
1.4 ± 0.7
2.4 ± 0.9
The genotype distribution in all SNPs were in line with Hardy-Weinberg genetic equilibrium in both CHD group and the control group (all P > 0.05, data not shown).
Genotype and allele frequencies
Distributions of CYP4F2 genotypes (N = 440)
Genotypes (n, %)
Allele (n, %)
OR (95% CI)
0.773(0.629 ~ 0.949)
0.877(0.664 ~ 1.158)
1.617(1.241 ~ 2.107)
0.876(0.670 ~ 1.147)
Haplotype distribution between case and control
A C T T
0.656 ~ 1.144
A G T T
0.622 ~ 1.039
G G G A
1.016 ~ 1.838
G G G T
2.241 ~ 8.510
G G T A
0.111 ~ 0.777
In this haplotype-based case–control study, we found GGGT haplotype carriers have higher risk but GGTA haplotype carriers have decreased risk for CHD in Han Chinese population. To the best of our knowledge, this is the first study to reveal the relation between CYP4F2 polymorphisms and CHD in Chinese Han population.
The genetic variation is the molecular basis of human genetic diversity. The T allele of CYP4F2 rs2108622 represents a missense mutation that results in the change of valine 433 to methionine (V433M). This change in the primary structure of CYP4F2 affects enzyme activity, leading to changes in drug metabolism, physiology, and pathophysiology. Cha et al.  through a genome-wide association study identified rs2108622 as a genetic determinant of warfarin responsiveness for Japanese. However, no association was found between this SNP and CHD by a genome-wide association study approach. CHD is caused by the interaction between environmental and genetic factors. In this study, an important human metabolic enzyme P450 gene family member- CYP4F2 gene was selected as the candidate gene to perform the case–control study, and we found that rs2108622 and rs3093105 in CYP4F2 gene was significantly associated with higher risk for CHD. We also found GGGT haplotype consisting of rs2108622-rs3093100-rs3093105-rs3093135 was the susceptibility haplotype of CHD. Our results were consistent with the results reported by Fu et al. , but inconsistent with results by Ward et al.  and Fava et al. . Ward et al. found that the A allele was a risk factor for hypertension. The other study by Fava et al.  found that the A allele was a risk factor for IS. This difference may be due to different races, different methodologies and different patient selection criteria.
Singh et al.  found that androgen-induced CYP4A8 expression reduced CYP2C23 expression and caused increased production of 20-HETE, then the epoxyeicosatrienoic acid (EET) decreased to affect the contraction of blood vessels. However, the exact mechanism of the susceptibility for CHD remains unclear.
In addition, although an elevated level of LDL-C and a decreased level of HDL-C in serum are independent risk factors for CHD, we did not find the LDL-C level and HDL-C level to be different between the CHD patients and the control subjects. This phenomenon may be the result from the treatment of decreased-cholesterol drugs (e.g., simvastatin, lovastatin) in CHD patients.
Several limitations of the present study should be noted. Firstly, these findings should be interpreted with caution because the population was only from Chinese population, this fact may reduce the possibility of confounding from ethnicity; Secondly, the present study is a hospital based case–control study, the selection bias cannot be avoidable and the subjects may not be representative of the general population; Finally, in the present study, we did not detect the amount of 20-HETE associated with CYP4F2 polymorphisms.
In conclusion, this study showed that both rs2108622 and rs3093105 in CYP4F2 gene were associated with CHD in Han Chinese population.
- Rossi A, Gaibazzi N, Dandale R, Agricola E, Moreo A, Berlinghieri N, Sartorio D, Loffi M, De Chiara B, Rigo F, Vassanelli C, Faggiano P: Aortic valve sclerosis as a marker of coronary artery atherosclerosis; a multicenter study of a large population with a low prevalence of coronary artery disease. Int J Cardiol. 2014, 172: 364-367. 10.1016/j.ijcard.2014.01.024View ArticlePubMed
- Sayols-Baixeras S, Lluís-Ganella C, Lucas G, Elosua R: Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants. Appl Clin Genet. 2014, 7: 15-32.PubMed CentralPubMed
- Grammer TB, Hoffmann MM, Renner W, Kleber ME, Winkelmann BR, Böhm BO, März W: Apolipoprotein E genotypes, circulating C-reactive protein and angiographic coronary artery disease: the Ludwigshafen risk and cardiovascular health study. Atherosclerosis. 2011, 215 (2): 487-493. 10.1016/j.atherosclerosis.2011.01.005View ArticlePubMed
- Xie X, Ma YT, Fu ZY, Yang YN, Ma X, Chen BD, Wang YH, Liu F: Association of polymorphisms of PTGS2 and CYP8A1 with myocardial infarction. Clin Chem Lab Med. 2009, 47 (3): 347-352.View ArticlePubMed
- Zheng YY, Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Ma X, Chen BD, Liu F: A novel polymorphism (901G > a) of C5L2 gene is associated with coronary artery disease in Chinese Han and Uyghur population. Lipids Health Dis. 2013, 12: 139-doi:10.1186/1476-511X-12-139PubMed CentralView ArticlePubMed
- Zhou L, Cai J, Liu G, Wei Y, Tang H: Associations between interleukin-1 gene polymorphisms and coronary heart disease risk: a meta-analysis. PLoS One. 2012, 7 (9): e45641-doi:10.1371/journal.pone.0045641PubMed CentralView ArticlePubMed
- Escalante B, Erlij D, Falck JR, McGiff JC: Effect of cytochrome-P450 arachidonate metabolites on ion-transport in rabbit kidney loop of Henle. Science. 1991, 251: 799-802. 10.1126/science.1846705View ArticlePubMed
- Ito O, Roman RJ: Role of 20-HETE in elevating chloride transport in the thick ascending limb of Dahl SS/Jr rats. Hypertension. 1999, 33: 419-423. 10.1161/01.HYP.33.1.419View ArticlePubMed
- Ribeiro CM, Dubay GR, Falck JR, Mandel LJ: Parathyroid hormone inhibits Na_-K_-ATPase through a cytochrome P-450 pathway. Am J Physiol. 1994, 266: F497-F505.PubMed
- Sanchez-Mendoza A, Lopez-Sanchez P, Vazquez-Cruz B, Rios A, Martinez-Ayala S, Escalante B: Angiotensin II modulates ion transport in rat proximal tubules through CYP metabolites. Biochem Biophys Res Commun. 2000, 272: 423-430. 10.1006/bbrc.2000.2807View ArticlePubMed
- Wang MH, Zhang F, Marji J, Zand BA, Nasjletti A: Laniado- Schwartzman M. CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. Am J Physiol Regul Integr Comp Physiol. 2001, 280: R255-R261.PubMed
- Liu X, Wu J, Liu H, Lai G, Zhao Y: Disturbed ratio of renal 20-HETE/EETs is involved in androgen-induced hypertension in cytochrome P450 4F2 transgenic mice. Gene. 2012, 505 (2): 352-359. doi:10.1016/j.gene.2012.02.029View ArticlePubMed
- Cai Y: Arachidonic acid cytochrome P450 4F2 in hypertension: what can we learn from a transgenic mouse model?. Kidney Int. 2009, 75 (12): 1253-1254. doi:10.1038/ki.2009.82View ArticlePubMed
- Stec DE, Roman RJ, Flasch A, Rieder MJ: Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics. 2007, 30 (1): 74-81.View ArticlePubMed
- Fava C, Montagnana M, Almgren P, Rosberg L, Lippi G, Hedblad B, Engström G, Berglund G, Minuz P, Melander O: The V433M variant of the CYP4F2 is associated with CHD in male Swedes beyond its effect on blood pressure. Hypertension. 2008, 52 (2): 373-380. 10.1161/HYPERTENSIONAHA.108.114199View ArticlePubMed
- Nakamura K, Obayashi K, Araki T, Aomori T, Fujita Y, Okada Y, Kurabayashi M, Hasegawa A, Ohmori S, Nakamura T: Yamamoto K.CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. J Clin Pharm Ther. 2012, 37 (4): 481-485. 10.1111/j.1365-2710.2011.01317.xView ArticlePubMed
- Fu Z, Nakayama T, Sato N, Izumi Y, Kasamaki Y, Shindo A, Ohta M, Soma M, Aoi N, Sato M, Ozawa Y, Ma Y, Matsumoto K, Doba N, Hinohara S: A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men. Mol Genet Metab. 2009, 96 (3): 145-147. 10.1016/j.ymgme.2008.11.161View ArticlePubMed
- Fava C, Montagnana M, Danese E, Sjögren M, Almgren P, Guidi GC, Hedblad B, Engström G, Minuz P, Melander O: The functional variant V433M of the CYP4F2 and the metabolic syndrome in Swedes. Prostaglandins Other Lipid Mediat. 2012, 98: 31-36. 10.1016/j.prostaglandins.2012.03.001View ArticlePubMed
- Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Huang D, Ma X, Chen BD, Liu F: Interaction between COX-2 G-765C and smoking in relation to coronary artery disease in a Chinese Uighur population. Clin Chem Lab Med. 2011, 49 (1): 55-60.View ArticlePubMed
- Zeng WT, Zheng QS, Huang M, Cen HJ, Lai Y, Chen WY, Zhao LZ, Leng XY: Genetic polymorphisms of VKORC1, CYP2C9, CYP4F2 in Bai. Pharmazie. 2012, 67 (1): 69-73.PubMed
- Munshi A, Sharma V, Kaul S, Al-Hazzani A, Alshatwi AA, Shafi G, Koppula R, Mallemoggala SB, Jyothy A: Association of 1347 G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertension and stroke. Mol Biol Rep. 2012, 39 (2): 1677-1682. 10.1007/s11033-011-0907-yView ArticlePubMed
- Cha PC, Mushiroda T, Takahashi A, Kubo M, Minami S, Kamatani N, Nakamura Y: Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet. 2010, 19: 4735-4744. 10.1093/hmg/ddq389View ArticlePubMed
- Ward NC, Tsai IJ, Barden A, van Bockxmeer FM, Puddey IB, Hodgson JM, Croft KD: A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension. 2008, 51 (5): 1393-1398. 10.1161/HYPERTENSIONAHA.107.104463View ArticlePubMed
- Singh H, Schwartzman ML: Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol Rep. 2008, 60: 29-37.PubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.